Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2023 | Exploring the potential of NK cells in mitigating relapse after allogeneic transplantation

Joseph McGuirk • 24 Apr 2023
EBMT 2023
General NK-Cell Therapy

Joseph McGuirk, DO, The University of Kansas Medical Center, Kansas City, KS, comments on the possibility of using natural killer (NK) cells to mitigate relapse after transplant. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Envision, Kite, AlloVir, BMS, Novartis, CRISPR, Nektar, Caribou Bio, Sana Technologies, Legend Biotech

More from Joseph McGuirk

3:12
CMV reactivation after matched unrelated donor & haploidentical transplantation
Joseph McGuirk • 24 Apr 2023
2:16
Phase I study of donor-derived γδ T cells as relapse prophylaxis post haplo/cy
Joseph McGuirk • 24 Apr 2023
5:32
CARBON: results of Phase I study of CTX110 allogeneic CRISPR-CAS9-engineered CAR-Ts in R/R LBCL
Joseph McGuirk • 24 Apr 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals